Immunocore Ltd
Immunocore develops ImmTAX, a platform of TCR bispecific immunotherapies for cancer, autoimmune diseases, and infectious diseases.
SCHEDULE 13G/ANov 16Latest SEC filing
Nov 9Latest story
November 2026
September 2026
August 2026
Immunocore develops ImmTAX, a platform of TCR bispecific immunotherapies for cancer, autoimmune diseases, and infectious diseases.
November 2026
September 2026
August 2026